Lv41
626 积分 2025-05-21 加入
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial
5天前
已完结
A Controlled Trial of Casodex™(Bicalutamide) vs. Flutamide,Each in Combination with LuteinisingHormone-Releasing HormoneAnalogue Therapy in Patients withAdvanced Prostate Cancer
5天前
已完结
Biodistribution and Radiation Dosimetry of [ 68 Ga]Ga-RAYZ-8009, a Glypican 3–Targeting Compound for Imaging of Hepatocellular Carcinoma
13天前
已完结
Pathogenesis and treatment of primary aldosteronism
18天前
已完结
Small cell lung cancer
1个月前
已完结
Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial
1个月前
已完结
Discovery of high-affinity ligands for prostatic acid phosphatase via DNA-encoded library screening enables targeted cancer therapy
1个月前
已完结
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
2个月前
已完结
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
2个月前
已完结
Preliminary evaluation of a novel PSMA-targeting radiopharmaceutical [68Ga]Ga/[177Lu]Lu–NYM032 for theranostic use in prostate cancer
2个月前
已完结
皖公网安备34019202002308
